Oximio, South Africa, solidifies its place as a key player in the medical cannabis industry with an additional resolution to its SAHPRA license.
Oximio, South Africa, is delighted to announce that it has secured a resolution to the South African Health Products Regulatory Authority (SAHPRA) licence for the handling of medical cannabis. This marks a significant milestone in the company’s journey and means that Oximio, South Africa, has the capability to support all licensed manufacturers and cultivating farms in the transportation of medical cannabis for exportation from South Africa.
Furthermore, Oximio, South Africa, is now able to accept medical cannabis for storage on behalf of local manufacturers and cultivators.
A premier distributor for international markets
The attainment of the licence places Oximio, South Africa, as a premier distributor for medical cannabis products for commercial or clinical trial purposes from Africa, extending the company’s reach to support the international market.
Mykola Nikolaiev, CEO, Oximio, says: “This marks a significant turning point in our operations, exemplifying our commitment to supporting the use of medical cannabis in clinical trials whilst underscoring our commitment to maintaining the highest standards of quality and care.”